Value of combination of 18F-fluorodeoxyglucose PET/CT and serum carbohydrate antigen125 and human epididymis protein4 in diagnosis of recurrent or metastatic ovarian cancers

ZHU Xiaxia; XU Junyan; LI Fei; YAO Zhifeng; PAN Herong; HU Silong; ZHANG Yingjian

您当前的位置：

首页 >

文章列表页 >

Value of combination of 18F-fluorodeoxyglucose PET/CT and serum carbohydrate antigen125 and human epididymis protein4 in diagnosis of recurrent or metastatic ovarian cancers

更新时间：2025-12-15

- Value of combination of 18F-fluorodeoxyglucose PET/CT and serum carbohydrate antigen125 and human epididymis protein4 in diagnosis of recurrent or metastatic ovarian cancers
- Vol. 25, Issue 1, Pages: 22-26(2016)
- 作者机构：
  
  1. 安徽医科大学第二附属医院核医学科,安徽,合肥,230601
  2. 复旦大学附属肿瘤医院核医学科，复旦大学上海医学院肿瘤学系,上海,200032
  3. 上海分子影像探针工程技术研究中心筹,上海,200032
  4. 复旦大学生物医学影像研究中心,上海,200032
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published Online：04 May 2016，
  
  Published：04 May 2016
- 稿件说明：
移动端阅览
朱夏夏,徐俊彦,李飞,等. ¹⁸F-脱氧葡萄糖PET/CT联合糖类抗原125、人附睾蛋白4检测在卵巢癌术后复发和转移中的诊断价值[J]. 肿瘤影像学, 2016, 25(1): 22-26
DOI：

朱夏夏,徐俊彦,李飞,等. ¹⁸F-脱氧葡萄糖PET/CT联合糖类抗原125、人附睾蛋白4检测在卵巢癌术后复发和转移中的诊断价值[J]. 肿瘤影像学, 2016, 25(1): 22-26 DOI：

摘要

目的：

探讨

F-脱氧葡萄糖(

F-fluorodeoxyglucose，

F-FDG)PET/CT联合血清糖类抗原125(carbohydrate antigen 125，CA125)及人附睾蛋白4(human epididymis protein 4，HE4)检测在卵巢癌术后复发和转移中的诊断价值。

方法：

回顾性分析63例卵巢癌患者术后PET/CT、CA125及HE4结果，与手术病理或临床随访资料相比较，判断三者对复发或转移性卵巢癌的诊断价值及相关性。

结果：

PET/CT诊断卵巢癌复发和转移的灵敏度、特异度、准确率、阳性预测值、阴性预测值分别为94.00%、84.62%、92.06%、95.92%、78.57%。CA125水平与复发和转移灶的最大标准摄取值(maximum standardized uptake value，SUV

max

)呈正相关(

=0.428，

=0.002)。PET/CT联合HE4诊断卵巢癌复发和转移的灵敏度、特异度、准确率、阳性预测值、阴性预测值分别为98.00%、84.62%、95.24%、96.08%、91.67%。

结论：

在诊断卵巢癌复发和转移中，

F-FDG PET/CT联合HE4具有最高的诊断效能。

Abstract

Objective:

To analyze and discuss the value of combination of

F-fluorodeoxyglucose (

F-FDG) PET/CT and serum carbohydrate antigen 125 (CA125) or human epididymis protein 4 (HE4) in the diagnosis of recurrent or metastatic ovariancancer.

Methods:

The postoperative results of PET/CT

serum CA125 and HE4 of 63 cases of ovarian cancer w

ere analyzed retrospectively. The results were compared with surgical pathology or clinical follow-up data

so as to evaluate their values in the diagnosis of recurrent or metastatic ovarian cancer.

Results:

The overall sensitivity

specificity

accuracy

positive and negative predictive values of PET/CT were 94.00%

84.62%

92.06%

95.92% and 78.57%. The corresponding values of combination of PET/CT and serum HE4 were 98.00%

84.62%

95.24%

96.08% and 91.67%. CA125 level was positively correlated with maximum standardized uptake value (SUV

max

) of the recurrent or metastatic region.

Conclusion:

The diagnostic efficiency of

F-FDG PET/CT combined with HE4 is high in the diagnosis of recurrent or metastatic ovarian cancer.

关键词

Keywords

references

Views

1561

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Value of 18F-fluorodeoxyglucose PET/CT imaging combined with serum carbohydrate antigen 125 and human epididymis protein 4 detection in diagnosis of ovarian malignancy

Correlation analysis between serum carbohydrate antigen 125 level and ¹⁸F-fluorodeoxyglucose PET/CT in detecting recurrence and metastasis of ovarian cancer

The value of multimodal imaging combined with CT, high-resolution MRI, and DWI in the diagnosis of postoperative anastomotic recurrence in rectal cancer

Association between the characteristics of conventional ultrasound combined with CEUS and the recurrence or metastasis of postoperative breast cancer

Predictive value of multi-parametric MRI radiomics model for local recurrence of advanced nasopharyngeal carcinoma

Related Author

LI Qiwen

LONG Wen

XIAO zizheng

ZHANG Yarui

HU Yingying

FAN Wei

ZHENG Rongliang

HAN Huijie

Related Institution

Department of Nuclear Medicine, Sun Yat-sen University Cancer Center

State Key Laboratory of Oncology in South China

Department of Radiology, Ziyang Central Hospital

Department of Radiology, Fuzhou Pulmonary Hospital

Department of Diagnostic Radiology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital

AI问答

⁰